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Objectives. This study sought o assess proinflammatory c to- 
kine levels in patients in the studies of left ventricular dysfunction 
trial (SOLVD) in relation to both their New York Heart Associa- 
tion functional classification and their neurohormonal status 
before randomization. 
Background. Elevated levels of tumor necrosis factor-alpha 
have been identified in 30% to 40% of patients with heart failure. 
However, it is unclear which subsets of patients with heart failure 
elaborate tumor necrosis factor-alpha. It is also unclear what the 
mechanism for the increased expression of proinflammatory 
cytokines i . 
Methods. Tumor necrosis factor-alpha nd interleukin-6 levels 
were analyzed by enzyme-linked immunoassay using randomly 
selected plasma samples from patients in functional classes I to 
III who were enrolled in neurohormonal substudies of the SOLVD 
trial; age-matched healthy subjects erved as the control group. 
Results. Plasma levels of tumor necrosis factor-alpha (p < 
0.001) were elevated in patients in functional classes I to IH 
([mean - SD] 1.95 + 0.54, 2.63 -+ 0.48, 6.4 -+ 1.9 pg/ml, 
respectively) compared with age-matched control subjects (0.75 + 
0.05 pg/ml) and were progressively elevated in relation to decreas- 
ing functional status of the patient. Plasma levels of interleukln-6 
(p < 0.001) were elevated in patients in functional classes I to III 
(3.3 -+ 0.55, 6.2 -+ 1.1, 5.22 -+ 0.9 pg/ml, respectively) compared 
with age-matched control subjects (1.8 -+ 0.5 pg/ml) and were 
progressively elevated in relation to decreasing functional status 
of the patient. Cox proportional-hazards analysis showed that 
there was a trend toward significance between plasma tumor 
necrosis factor-alpha (p < 0.07) and survival, whereas there was 
no significant relation for plasma interleukin-6 (p < 0.72). Except 
for atrial natriuretic factor, which correlated weakly (r = 0.23, 
p = 0.04) with circulating tumor necrosis factor-alpha levels, 
there was no significant correlation between eurohormonal and 
proinflammatory c tokine levels. 
Conclusions. Circulating levels of proinflammatory c tokines 
increase in patients as their functional heart failure classification 
deteriorates. Moreover, activation of the neurohumoral xis is 
unlikely to completely explain the elaboration of proinflammatory 
cytokines in heart failure. 
(J Am Coil Cardio11996;27:1201- 6) 
Despite the repeated observation that patients with heart 
failure have elevated levels of tumor necrosis factor-alpha in
their plasma (1-6), the clinical significance of this finding 
remains unknown. Indeed, although the elaboration of tumor 
necrosis factor-alpha in patients with heart failure was pro- 
posed originally as a biochemical mechanism for the cachexia 
that occurs in this syndrome (1), it is also known that overex- 
pression of this proinflammatory c tokine can produce left 
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ventricular dysfunction, pulmonary edema and cardiomyopa- 
thy in human subjects (7-9). Taken together, these latter 
observations have given rise to the intriguing notion that 
overcxpression f tumor necrosis factor-alpha might actually 
contribute to the primary progression of heart failure (10,11). 
However, the countervailing point of view that has been raised 
is that the elaboration of tumor necrosis factor-alpha in heart 
failure may simply be an epiphenomenon r marker of "dis- 
ease severity," with little or no bearing on the primary pro- 
gression of the disease process itself. 
Central to the validation of the so-called cytokine hypoth- 
esis for heart failure is a clearer appreciation ofwhich subsets 
of patients with heart failure elaborate tumor necrosis factor- 
alpha. That is, although previous studies have consistently 
identified elevated levels of tumor necrosis factor-alpha in 
patients with heart failure, 0nly 30% to 40% of the patients in 
these studies actually have elevated circulating levels of tumor 
necrosis factor-alpha (1,6). Thus, for reasons that are unclear, 
not all patients with heart failure appear to elaborate tumor 
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necrosis factor-alpha. Moreover, the mechanism responsible 
for tumor necrosis factor-alpha production in heart failure is 
not immediately apparent. Because proinflammatory c tokines 
have traditionally been thought o be produced by the immune 
system, we and others have suggested that neurohumoral 
activation might stimulate proinflammatory c tokine produc- 
tion through a mechanism that involves primary myocardial 
injury with secondary activation of the immune system (6,10). 
Nonetheless, although this hypothesis logical, it has not been 
tested in a diverse group of patients with heart failure. 
Accordingly, to address these questions, we examined proin- 
flammatory cytokine levels in patients with symptomatic and 
asymptomatic left ventricular dysfunction, each of whom had 
complete neurohormonal studies performed on entry into an 
extremely well characterized multicenter clinical trial: the 
Studies of Left Ventricular Dysfunction (SOLVD) (12,13). 
Methods  
Patients. This study included a subset of the subjects 
enrolled in the neurohormonal substudies in SOLVD (12,13). 
At the request of the investigators, the SOLVD Data Coordi- 
nating Center (The University of North Carolina at Chapel 
Hill, Chapel Hill) generated a list of 90 patients in New York 
Heart Association functional classes I to III (30 patients/class). 
Insofar as few patients in the SOLVD trial had severe heart 
failure, there was not a sufficient number of patients in 
functional class IV in the neurohormonal substudies to be 
included as a separate group. The major selection criterion for 
inclusion in this study was that each patient had to have had a 
full set of neurohormonal studies (plasma norepinephrine, 
plasma renin, arginine vasopressin and atrial natriuretic factor) 
performed at baseline before randomization i to either the 
treatment or prevention arms of the SOLVD trial. Patients for 
this study were chosen randomly and were selected solely by 
the SOLVD Data Coordinating Center. 
Once the list of randomly generated patient identification 
numbers was provided by the SOLVD Data Coordinating 
Center, the plasma samples that corresponded to the appro- 
priate patient identification umbers were obtained from the 
University of Texas Medical School at Houston, Texas. These 
plasma samples, which had been maintained at -70°C, were 
originally collected for the analysis of neurohormones in the 
SOLVD trial. Thus, proinflammatory cytokine levels were 
always measured from the same plasma samples that were used 
to perform the neurohormonal ssays. These samples had been 
collected into prechilled evacuated tubes containing ethyl- 
enediaminetetraacetic acidand centrifuged at 4°C at 2,500 rpm 
for 12 rain within 1 h of collection (14); thus, the handling of 
these samples was appropriate for collection of cytokines as 
well (15,16). All plasma samples used in this study had been 
thawed once for the measurement of neurohormonal measure- 
ments and then refrozen at -70°C after analysis. Previous 
studies have shown that tumor necrosis factor-alpha nd 
interleukin-6 levels are unaffected by up to three freeze-thaw 
cycles (17). To avoid proteolysis, 0.1/zmol/liter phenylmethyl- 
sulfonyl fluoride was added to the plasma samples. 
Once these samples were located, they were transferred to 
the Cardiac Cytokine Laboratory at the Houston Veterans 
Affairs Medical Center. All plasma samples were identified by 
number only; the personnel in the Cardiac Cytokine Labora- 
tory were unaware of the functional class of the patients or of 
any other demographic, hemodynamic, outcome or biochemi- 
cal data for the patients from whom the samples had been 
obtained. 
On the basis of preliminary analysis of cytokine levels in 
patients with heart failure in our laboratory, we estimated that 
a sample size of -22 patients/functional class would have 
sufficient power (0.85) to determine a significant difference 
(p < 0.05) for a twofold increase in cytokine levels between 
functional groups. Accordingly, patient samples were selected 
from the frozen plasma samples provided by the University of 
Texas Medical School in the exact rank order that was 
provided by the SOLVD Data Coordinating Center; if a 
sample was missing or had insufficient plasma remaining for a 
complete cytokine analysis (<1,000 tzl), the next patient iden- 
tification code on the list was chosen, and the plasma sample 
corresponding to that number was used instead. We were able 
to analyze atotal of 22 patients in functional class I, 20 patients 
in class II and 21 patients in class III. After the plasma samples 
had been analyzed, the SOLVD Data Coordinating Center was 
recontacted, and the relevant demographic, hemodynamic and 
biochemical data were obtained from the SOLVD data bases. 
Proinflammatory cytokine levels. Cytokine measurements 
for tumor necrosis factor-alpha nd interleukin-6 were per- 
formed using commercially available (Quantikine HS, R & D 
Systems) immunoassays, aswe described previously (18). The 
intraassay coefficients of variation for the tumor necrosis 
factor-alpha nd interleukin-6 kits are 6.1% and 3.7%, respec- 
tively; the interassay coefficients of variation for the tumor 
necrosis factor-alpha and interleukin-6 kits are 7.8% and 3.6%, 
respectively. The diluent for these assays is designed to reduce 
possible interference from heterophilic antibodies as well as 
from complement (16). As additional precautions against 
possible interference, we performed "spiking experiments," 
using concentrations of recombinant cytokines found in pa- 
tients with advanced heart failure, as well as serial dilutions 
(1/2, 1/4, 1/10) on the plasma to be certain that the level of 
cytokine immunoreactivity declined in a manner parallel to the 
standard curve (16). 
To provide reference values for tumor necrosis factor-alpha 
and interleukin-6 that would be age-appropriate for the pa- 
tients enrolled in SOLVD, we obtained plasma samples from 
14 age-matched normal volunteers who were known to be free 
of cardiovascular disease or other comorbid conditions. These 
samples were then analyzed for tumor necrosis factor-alpha 
and interleukin-6 exactly as described before. 
Statistical analysis. Neither the neurohormonal data nor 
the cytokine data were normally distributed; therefore, the 
data were subjected to logarithmic transformation (14). How- 
ever, to permit comparison with results from other studies, 
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Table 1. Demographic, Hemodynamic and Biochemical 
Characteristics of Patients From the SOLVD Trial 
NYHA Functional Classification 
Class I Class II Class III p 
(n = 22) (n = 20) (n = 21) Value 
Age (yr) 59.3 _+ 2.8 62.0 _ 2.4 62.9 __ 2.3 NS 
Male/female (no.) 22/0 19/2 15/5 
LVEF 28.9 + 1.1 25.1 _+ 1.7 24.9 - 1.3 NS 
CT ratio 0.51 _+ 0.01 0.54 _+ 0.01 0.51 _+ 0.02 NS 
MAP (mm Hg) 91.9 _+ 2.6 92.7 _+ 1.8 94.1 _ 1.5 NS 
Hematocrit (%) 42.8 - 0.7 42.2 _+ 0.8 41.4 _+ 1.2 NS 
Sodium (mEq/liter) 139.7 _+ 0.44 141 _+ 0.6 140.0 _ 0.6 NS 
BUN (mg/dl) 15.8 _+ 1.2 18.7 _+ 1.6 19.9 ___ 1.6 NS 
Creatinine (mg/dl) 1.1 + 0.03 1.3 _+ 0.09 1.2 - 0.07 NS 
PNE (pg/ml) 432.0 _+ 29 502.6 _+ 92.1 661.4 + 125.5 0.08 
PRA (ng/ml per h) 1.3 _+ 1.3 1.7 - 0.3 4.0 --- 1.3 0.054 
AVP (pg/ml) 2.7 -- 0.6 2.8 _+ 0.3 3.05 -+ 0.38 NS 
ANP (pg/ml) 118.8 _+ 2.7 115.9 _+ 13.8 172.7 + 20.8 0.052 
Data presented are mean value _+ SE. ANP = atrial natriuretic peptide; 
AVP = arginine vasopressin; BUN = blood urea nitrogen; CT = cardiothoracic; 
LVEF = left ventricular ejection fraction; MAP = mean arterial pressure; 
NYHA = New York Heart Association; PNE = plasma norepinephrine level; 
PRA = plasma renin activity. 
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Figure 1. Levels of tumor necrosis factor-alpha (TNF-a) in normal 
subjects and patients with New York Heart Association (NYHA) 
functional c ass I to III heart failure. The tumor necrosis factor-alpha 
levels were determined from frozen plasma samples from age-matched 
subjects who were free of heart disease and from patients with 
asymptomatic nd symptomatic left ventricular dysfunction (see Meth- 
ods for details). Compared with age-matched normal subjects (open 
bar), the plasma tumor necrosis factor-alpha levels for patients with 
heart failure (solid bars) were elevated in direct proportion to the 
patients infunctional classes I to III (p < 0.001 by analysis of variance). 
*p < 0.05 versus normal subjects. 
both the cytokine and neurohormonal cytokine data are pre- 
sented as mean value _+ SE. One-way analysis of variance was 
used to test for mean differences in all demographic, hemody- 
namic, biochemical and cytokine measurements in functional 
classes I to III; post hoc multiple comparison testing was 
performed to test for differences from control values (Dun- 
nett) or to test for differences between individual functional 
classes (Student-Newman-Keuls). The prognostic value of 
increased proinflammatory cytokine levels was examined using 
a Cox proportional hazards regression analysis (Statistica, 
version 4.0). Linear regression analysis of the log-normalized 
data was used to test for significant relations between cytokine 
and individual neurohormone levels. A stepwise linear egres- 
sion analysis was used to test for relations between cytokines 
and combinations of neurohormones (RS-1, version 4.01a). 
For these studies, plasma norepinephrine, plasma renin, argi- 
nine vasopressin and atrial natriuretic factor levels were en- 
tered into the statistical model together or in pairs to deter- 
mine whether there was a significant relation between 
combinations of neurohormones and tumor necrosis factor- 
alpha or interleukin-6. Significant differences were said to exist 
at p < 0.05. 
Results  
Patients: demographic, hemodynamic and biochemical 
characteristics. As shown in Table 1, the demographic, hemo- 
dynamic and biochemical characteristics of the data from the 
subset of patients enrolled in the neurohormonal substudies of 
the SOLVD trial were consistent with the data reported for the 
overall cohort of patients enrolled in the treatment and 
prevention arms of the SOLVD trial (19). Patients in func- 
tional classes I to III were similar with respect o age, left 
ventricular ejection fraction, cardiothoracic ratio, mean arte- 
rial blood pressure, hematocrit, serum sodium, blood urea 
nitrogen and creatine. Although the values for plasma norepi- 
nephrine and arginine vasopressin each increased with increas- 
ing heart failure class, these values were not significant statis- 
tically among the different classes, consistent with previous 
reports from the SOLVD registry that showed that levels of 
arginine vasopressin did not deteriorate with functional class 
and that levels of norepinephrine only deteriorated in patients 
in functional class IV (Fig. 2 in reference 14). However, there 
was a trend toward significance among roups for plasma renin 
activity (p -- 0.054) and atrial natriuretic factor (p -- 0.052) 
among functional classes, both of which are consistent with 
previous findings from the SOLVD registry, which showed that 
plasma renin activity and atrial natriuretic peptide levels both 
increased as the functional class of the patient deteriorates 
(Fig. 2 in reference 14). The mean age of the normal control 
subjects used in this study was 59.6 _+ 1.9 years and did not 
differ statistically from the ages of the patients with heart 
failure in this study (analysis of variance (ANOVA), p = 0.65). 
Proinflammatory cytokine levels. Figure 1 shows that com- 
pared with age-matched control subjects who were free of 
cardiovascular disease or other comorbid conditions, there was 
a progressive increase in peripheral circulating levels of tumor 
necrosis factor-alpha in direct relation to the patient's func- 
tional class. Indeed, there was an eightfold increase in the 
tumor necrosis factor-alpha levels in patients with functional 
class III compared with control subjects. Similar findings were 
obtained with respect o the analysis of interleukin-6 levels in 
relation to functional class. As shown in Figure 2, there was an 
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Figure 2. Levels of interleukin-6 (IL-6) in normal subjects and pa- 
tients with New York Heart Association (NYHA) functional class I to 
III heart failure. The interleukin-6 levels were determined from frozen 
plasma samples from age-matched subjects who were free of heart 
disease and from patients with asymptomatic and symptomatic left 
ventricular dysfunction (see Methods for details). Comparison with 
age-matched normal subjects (open bar), the plasma levels for 
interleukin-6 in patients with heart failure (solid bars) were elevated 
maximally inpatients in functional class II and did not increase further 
(analysis of variance, p < 0.001). *p < 0.05 versus normal subjects. 
increase in plasma levels of interleukin-6 in patients in func- 
tional classes I to IlL However, in contrast o the findings 
observed with tumor necrosis factor-alpha, the circulating level 
of interleukin-6 was maximal in patients in functional class II 
and did not increase further in patients in functional class Ill. 
One-way ANOVA of the log-transformed data indicated that 
there were significant overall differences in the levels of tumor 
necrosis factor-alpha (p < 0.001) and interleukin-6 (p < 0.001) 
in patients with functional class I to III heart failure. Post hoc 
analysis of variance testing (Dunnett) indicated that there were 
significant differences (p < 0.05) in the levels of tumor necrosis 
factor-alpha nd interleukin-6 in patients in functional classes 
II and III compared with age-matched control subjects, 
whereas there was no significant difference (p > 0.05) in tumor 
necrosis factor-alpha levels in patients in functional class I 
compared with normal subjects. In addition, the level of tumor 
necrosis factor-alpha was significantly higher (p < 0.05) in 
patients in functional class III than in those in functional 
classes I and II (Student-Newman-Keuls), whereas the level of 
interleukin-6 was not different between patients in functional 
classes II and III but was significantly higher (p < 0.05) in 
functional class II than functional class I. 
Relation between tumor necrosis factor-alpha and 
interleuldn.6 levels. Figure 3 shows the relation between 
tumor necrosis factor-alpha nd interleukin-6 levels in normal 
control subjects and patients in functional classes I to III. 
When the log-normalized ata were examined, there was a 
significant linear relation between the levels of tumor necrosis 
factor-alpha and interleukin-6 (r = 0.47, p < 0.0001, slope p < 
0.001). Similar findings were obtained when the untransformed 
data were examined using a nonparametric analysis (Spearman 
R = 0.54, p < 0.00001). Thus, although the correlation 
between tumor necrosis factor-alpha nd interleukin-6 was 
modest, these data suggest that there may be a relation 
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Figure 3. Correlation between tumor necrosis factor-alpha nd 
interleukin-6 levels. The relation between log tumor necrosis factor- 
alpha and log interleukin-6 was examined for normal subjects (open 
circles) and patients in functional class I (open squares), class II (open 
triangles) and class llI (solid circles). Linear regression analysis 
showed that there was a statistically significant, albeit modest, positive 
correlation between the levels of tumor necrosis factor-alpha nd 
interleukin-6 (r = 0.47, p < 0.0001, slope p < 0.001). 
between the biosynthesis of tumor necrosis factor-alpha nd 
interleukin-6. 
Relation between cytokine and neurohormonal evels. 
Table 2 shows that there was no significant correlation between 
interleukin-6 and plasma norepinephrine, plasma renin activ- 
ity, arginine vasopressin or atrial natriuretic factor levels. 
Similarly, there was no significant correlation between tumor 
necrosis factor-alpha nd plasma norepinephrine, plasma re- 
nin activity or arginine vasopressin levels. However, there was 
a statistically significant correlation (p < 0.005) between the 
level of atrial natriuretic peptide and tumor necrosis factor- 
alpha. To determine whether a combination of two or more 
neurohormones was responsible for the expression of cyto- 
kines, we performed a stepwise linear regression analysis in 
which all of the neurohormones were added to the statistical 
model together or in pairs to determine whether some combi- 
nation of ncurohormones might be responsible for the in- 
creased expression of proinflammatory c tokines. This analysis 
showed that the statistical fit for tumor necrosis factor-alpha 
and interleukin-6 was not improved by using a model that 
included all of the neurohormones or various combinations of 
neurohormones. 
Table 2. Correlation Between Neurohormonal nd Cytokine Levels 
TNF-Alpha Interleukin-6 
r Coeff p Value r Coeff p Value 
PNE -0.02 0.84 0.02 0.87 
PRA 0.12 0.35 -0.06 0.64 
AVP 0.14 0.29 0.15 0.24 
ANP 0.35 0.005 -0.001 0.99 
Coeff = coefficient; IL-6 = interleukin-6; TNF-Alpha = tumor necrosis 
factor-alpha; other abbreviations a in Table 1. 
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Table 3. Relation of Cytokine and Neurohormonal Levels to 
Survival According to a Cox Proportional Hazards Model 
Chi-Square p Value 
YNF-alpha 5.3 0.07 
IL-6 0.6 0.72 
PNE 1.7 0.41 
ANP 5.9 0.05 
Abbreviations as in Tables 1 and 2. 
Proinflammatory cytokines and all-cause mortality. At the 
end of the 48-month follow-up period, 14 patients (22.22%) 
had died, and 49 (77.78%) patients in functional classes I to III 
remained alive. To determine whether tumor necrosis factor- 
alpha and interleukin-6 levels were related to survival, we 
performed a Cox proportional hazards analysis after adjusting 
for the main treatment effect with an angiotensin-converting 
enzyme inhibitor. Table 3 shows that there was a trend toward a 
significant relation (p = 0.07) for tumor necrosis factor-alpha; 
however, there was no significant relation for interleukin-6 (p = 
0.72). A similar though slightly improved statistical trend was 
observed for tumor necrosis factor-alpha when a univariate Cox 
proportional hazards analysis was performed in patients treated 
with placebo alone (p = 0.055). In addition to examining the 
relation between proinflammatory cytokines and mortality, we 
also examined the univariate relation for two neurohormones that 
have been previously shown to be related to survival in patients 
with heart failure: plasma norepinephrine (20) and atrial natri- 
uretie factor (21). As shown in Table 3, after adjusting for the 
main treatment effect with angiotensin-converting e zyme inhib- 
itor, there was no significant relation (p = 0.41) for plasma 
norepinephrine inpatients in functional classes I to III, consistent 
with the observation that plasma norepinephrine l vels are sig- 
nificantly elevated in patients in functional class IV (14). In 
contrast, here was a trend toward a significant relation for atrial 
natriuretic factor (p = 0.05) and survival. In addition, we also 
used a multivariate model to determine whether adding atrial 
natriuretic factor and plasma norepinephrine as covariables 
would add significant prognostic information to the model after 
the introduction of plasma tumor necrosis factor-alpha. This 
analysis howed that plasma tumor necrosis factor-a!pha was the 
strongest overall predictor of survival but that adding atrial 
natriuretic factor and plasma norepinephrine did not add signif- 
icant new prognostic information to the model (p = 0.10). 
Nonetheless, we cannot exclude the possibility that atrial natri- 
uretic factor and plasma norepinephrine may have been stronger 
predictors of survival if patients in functional class IV had been 
included in this study. 
Discuss ion  
Analysis of the proinflammatory c tokine levels in patients 
enrolled in the SOLVD trial provides answers, at varying levels 
of completeness, to two of the questions that were raised at the 
outset of this study. In response to the first question of which 
subsets of patients with heart failure elaborate proinflamma- 
tory cytokines, the data presented herein suggest hat tumor 
necrosis factor-alpha (Fig. 1) and interleukin-6 levels (Fig. 2) 
are both elevated in relation to deteriorating functional clas- 
sification. Although this finding does not necessarily establish a
cause-and-effect relation between elevated cytokine levels and 
heart failure progression, it is nonetheless important to recog- 
nize that overproduction of tumor necrosis factor-alpha is 
associated with many of the hallmarks of symptomatic heart 
failure, including worsening left ventricular dysfunction, pul- 
monary edema and cardiac remodeling (7,9). In this regard, 
the Cox proportional hazards model suggested that there was 
a trend toward significance for the relation between tumor 
necrosis factor-alpha nd patient survival (Table 3), particu- 
larly in the patients who were randomized to placebo. Al- 
though this relation did not reach statistical significance, the 
statistical design of this study was not powered to address this 
specific question. Moreover, it is possible that if patients in 
functional class IV (in whom tumor necrosis factor-alpha levels 
are higher [22]) had been included in this study, the prognostic 
importance of plasma tumor necrosis factor-alpha levels may 
have been more apparent. Taken together, these findings arc 
consistent with the point of view that overexpression f proin- 
flammatory cytokines in patients with depressed left ventricu- 
lar ejection fraction may be one of several different maladap- 
tive biochemical mechanisms that impel the patient from 
asymptomatic o symptomatic heart failure (11). 
Correlation between proinflammatory cytokines and neu- 
rohormonal activation. In response to the second question of 
whether neurohormonal ctivation was responsible for the 
increased expression of proinflammatory c tokines in patients 
with heart failure, the data suggest hat, save for atrial natri- 
uretic factor, which correlated weakly with circulating tumor 
necrosis factor-alpha levels, there was no significant correla- 
tion between eurohormonal nd proinflammatory c tokine 
levels (Table 2). Although the present study did not examine 
the relation between proinflammatory c tokines and neurohor- 
moues in patients in functional class IV, this question was 
addressed in a recent study in which 16 patients with "chronic 
stable" functional class IV heart failure were studied during 
the institution of vasodilator therapy (4). In that report, there 
was no suggestion of a direct relation between plasma tumor 
necrosis factor-alpha nd norepinephrine (r = 0.17, p = 0.52) 
or plasma renin activity (r = 0.41, p = 0.11) at the time of the 
entry of patients into the study. Thus, the aggregate data 
suggest hat the neurohormonal ctivation is unlikely to com- 
pletely explain the elevated levels of proinflammatory c to- 
kines that occur in patients with heart failure. This statement 
notwithstanding, we cannot discount he possibility that we 
might have observed a more significant relation between 
neurohormonal nd proinflammatory c tokines had the pa- 
tient cohort of this study been larger and included patients in 
functional class IV. Although the correlation between the level 
of tumor necrosis factor-alpha nd atrial natriuretic factor in 
this study was statistically significant, this correlation was 
relatively weak and therefore did not imply a strong causal 
relation. Nonetheless, we found this relation intriguing be- 
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cause circulating levels of this peptide increase in patients with 
worsening heart failure and are also correlated with patient 
survival (21). Thus, increased circulating levels of tumor ne- 
crosis factor-alpha, interleukin-6 and atrial natriuretic factor 
may serve as "biochemical markers" for the progression from 
asymptomatic to symptomatic left ventricular dysfunction. 
Conclusions. This simple study expands on previous stud- 
ies that have described elevated levels of tumor necrosis 
factor-alpha and interleukin-6 in heart failure (1-6,23,24) by 
demonstrating that peripheral circulating levels of proinflam- 
matory cytokines increase in patients in direct relation to 
increasing heart failure symptomatology. This study further 
suggests that the elaboration of proinflammatory cytokines in 
heart failure is unlikely to be explained completely by activa- 
tion of the neurohormonal system. Thus, although the source 
and stimulus for proinflammatory cytokine elaboration in 
heart failure remain elusive for the present, the results of this 
study should at least serve the heuristic purpose of focusing 
future experimental and clinical investigations on these inter- 
esting, if not important questions. 
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